13 results about "Acyltransferases" patented technology

The invention discloses an aspergillus niger recombinant strain for degrading vomitoxin and application thereof, and belongs to the field of gene engineering. In order to solve the problem that a method for efficiently degrading vomitoxin is lacked in the prior art, the invention provides an aspergillus niger recombinant strain for degrading vomitoxin, the aspergillus niger strain for co-expressing FsTRI12 is taken as a recipient bacterium, a vomitoxin acetyltransferase gene segment is selected, an intracellular gene expression vector is constructed, and a homozygous aspergillus niger recombinant strain is screened. The aspergillus niger recombinant strain provided by the invention can be applied to degradation of vomitoxin, provides a new choice for effectively solving the vomitoxin pollution problem in cereal raw materials and feeds, reducing grain loss and guaranteeing food and feed safety, and has potential industrial application prospects.

The present invention relates to the fields of fatty acid- and polyketide synthesis, and protein engineering. In particular, it relates to methods of using altered acyltransferases having an altered coenzyme specificity for acyl group transfer and polyketide synthesis.

The present invention relates to the fields of fatty acid- and polyketide synthesis, and protein engineering. In particular, it relates to methods of using altered acyltransferases having an altered coenzyme specificity for acyl group transfer and polyketide synthesis.

The invention discloses two novel lignin monomer p-hydroxybenzoyl transferases, which are respectively PoPHBMT1 derived from Ocean Paeonia suffruticosa and PaPHBMT1 derived from Australian Paeonia suffruticosa, and the two novel lignin monomer p-hydroxybenzoyl transferases are suitable for realizing plant lignin p-hydroxybenzoyl modification in species with high content of H-type lignin or G-type lignin. The method has important significance for utilizing and modifying plant biomass resources rich in G-type lignin units and / or H-type lignin units.

The present invention relates to the fields of fatty acid- and polyketide synthesis, and protein engineering. In particular, it relates to methods of using altered acyltransferases having an altered coenzyme specificity for acyl group transfer and polyketide synthesis.

Provided are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

This invention discloses an acetyltransferase ARD1 inhibitor, D753-0266, and its application in the treatment of colorectal cancer, belonging to the field of biomedical technology. Through molecular dynamics simulations and binding energy calculations, it was found that the binding energy of D753-0266 to NAA10 can reach -68.12 kcal / mol. In vitro experiments show that D753-0266 can directly bind to and stabilize the ARD1 protein, downregulate its expression level, and dose-dependently inhibit the proliferation of colorectal cancer cells, while significantly inhibiting cell migration and colony formation. In vivo experiments show that D753-0266 effectively inhibits tumor growth in a mouse xenograft model and is well-tolerated. This inhibitor fills a research gap in the field of ARD1 targeting and can be used to prepare colorectal cancer therapeutic drugs, possessing high specificity and clinical translational potential.

The invention discloses an acetyltransferase ARD1 inhibitor D753-0266 and application of the acetyltransferase ARD1 inhibitor D753-0266 in colorectal cancer treatment, and relates to the technical field of biological medicines. Through molecular dynamics simulation and binding energy calculation, it is found that the binding energy of D753-0266 and NAA10 can reach-68.12 kcal / mol. In-vitro experiments show that D753-0266 can be directly combined with and stabilize ARD1 protein, down-regulate the expression level of the ARD1 protein, inhibit colorectal cancer cell proliferation in a dose-dependent manner, and remarkably inhibit cell migration and clone formation capability at the same time. In-vivo experiments show that the D753-0266 can effectively inhibit tumor growth in a mouse transplantation tumor model and has good tolerance. The inhibitor fills up the research blank in the field of targeting ARD1, can be used for preparing colorectal cancer treatment drugs, and has high specificity and clinical transformation potential.

The invention belongs to the technical field of plant genetic engineering, and particularly relates to application of ZmSNAT1 protein and a coding gene thereof in catalyzing 5-hydroxytryptamine to synthesize N-acetyl-5-hydroxytryptamine, and the amino acid sequence of the ZmSNAT1 protein is shown as SEQ ID NO.1. The invention further discloses a preparation method of the ZmSNAT1 protein. According to the invention, the first 5-hydroxytryptamine-N-acetyltransferase ZmSNAT1 in the corn body is obtained through identification, and the ZmSNAT1 has the functions of converting 5-hydroxytryptamine into N-acetyl-5-hydroxytryptamine (NAS) and converting 5-methoxytryptamine into melatonin through in-vitro experiment determination, and has relatively high catalytic activity; and the ZmSNAT1 gene is found to have response to heat stress and drought stress, and a foundation is laid for further research on melatonin biosynthesis and the regulation effect of melatonin in plant growth and abiotic stress response.

The invention discloses rice oil with high active substance content and a preparation method thereof, and relates to the technical field of deep processing of edible oil, raw material refining pretreatment is carried out to guarantee material reaction suitability, a specific composite enzymatic hydrolysis system is adopted to directionally cut off characteristic chemical bonds of a binding state precursor under low-temperature, light-proof and oxygen-controlled conditions, and the active substance content of the rice oil is high. Active substrates such as free ferulic acid and free phytosterol are efficiently released; in an in-situ solid-phase system of the rice bran, directional conversion of a free substrate to fat-soluble oryzanol, sterol ferulate and high-activity tocotrienol is realized through synergistic catalysis of immobilized lipase and acyltransferase, multi-step separation and purification are not needed, a whole-process low-temperature mild oil extraction and low-loss precise refining process is matched, and the yield is high. And degradation and loss of active components are reduced to the maximum extent.

The application belongs to the technical field of biological medicine, and provides application of a peptide in a histone acetyltransferase MOF biological activity inhibitor, and an amino acid sequence of the peptide is PYQRRGYGKF, as shown in SEQ ID No. 1. The application finds a biological activity domain of the histone acetyltransferase MOF, identifies an amino acid sequence capable of inhibiting the biological activity of the MOF, and proves that the sequence small molecule peptide can play a role in inhibiting the biological function and acetylation catalytic activity of the MOF, and can be applied as the MOF inhibitor to alleviate or treat diseases caused by the increase of the biological activity of the MOF.

Provided are compounds of formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

The application discloses a recombinant engineering bacterium with ThlA gene knockout and industrial gas source domestication and application thereof. The recombinant engineering bacterium is Clostridium autoethanogenum engineering bacterium with the preservation number of GDMCC No: 67962. The application optimizes carbon flow distribution of the C. autoethanogenum from the metabolic pathway level by using the CRISPR / Cas9 gene editing technology to knock out the acetyl coenzyme A acetyltransferase coding gene ThlA (gene number: CLAU_0409), and reduces by-product generation. On this basis, the gene edited strain is further subjected to laboratory directional domestication to strengthen the tolerance and adaptability of the strain to the complex environment of steel industry tail gas, and finally the growth rate, ethanol selectivity and ethanol yield of the strain are simultaneously improved, thereby providing core strain support for industrialization landing of resource utilization of the steel industry tail gas.